Dabigatran etexilate (dabigatran) is a novel, oral, reversible, direct thrombin inhibitor that exhibits several advantages over warfarin for therapeutic anticoagulation. The predictable pharmacokinetic profile and minimal food and drug interactions of dabigatran allow for a fixed-dosing regimen and obviate the need for routine laboratory monitoring. Dabigatran has been approved in the United States for prevention of stroke in patients with nonvalvular atrial fibrillation and in the European Union and other countries for primary prevention of thromboembolic events after total knee or hip replacement. More indications for the use of dabigatran are under review by regulatory authorities and are undergoing active clinical investigation. Due to its rapid onset of action, dabigatran may omit the need for a parenteral anticoagulant for acute treatment of thromboembolic conditions. Because wide-scale use of dabigatran is expected in the near future, hospitalists need to familiarize themselves with this agent. The lack of a standardized reliable laboratory method to monitor the anticoagulant effects of dabigatran complicates verifying compliance, measuring the effects of drug interactions, evaluating cases of dabigatran toxicity, and conducting preoperative evaluations. The lack of an antidote to dabigatran complicates the management of toxicity and makes it largely supportive. The elimination of dabigatran is dependent on renal function, with the potential for drug accumulation and toxicity with renal impairment. The noninferiority design of the clinical trials that evaluated dabigatran and the absence of long-term safety and efficacy data and issues related to the cost effectiveness of dabigatran should all be considered when prescribing this agent. Journal of Hospital Medicine 2012;7:262–269. © 2011 Society of Hospital Medicine.

Vitamin K antagonists (VKAs) such as warfarin have been the backbone of oral anticoagulation in clinical practice since the middle of the last century. Despite their efficacy, VKAs have well-recognized limitations that have led to their underutilization in patients who would otherwise be candidates for oral anticoagulation.1–4 These limitations include a narrow therapeutic window and significant intra- and interindividual variability in dose requirements as well as numerous drug–drug and drug–food interactions.5–9 Therefore, VKAs require close laboratory monitoring to prevent excessive or under-anticoagulation, and maintaining therapeutic anticoagulation with VKAs remains a challenging task in many patients.2 It has been shown that 30%–50% of international normalized ratio (INR) results fall outside of the targeted therapeutic range.10,11 Consequently, it is not surprising that warfarin is a common cause of medication-related emergency room visits.12 Despite many fruitless years of searching for better alternatives, VKAs have remained the mainstay of oral anticoagulation for more than 60 years.8

An ideal anticoagulant would be orally administered, effective, safe, exhibit a predictable pharmacokinetic profile and a low potential for drug or dietary interactions, and therefore would not require routine laboratory monitoring.2,5,13 Other desirable characteristics would include a rapid onset of action to decrease or eliminate the need for bridging therapy, and rapid reversibility with or without an antidote.8,13 To date, no oral anticoagulant has been developed that possesses all of these desired characteristics. Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s.14 In the following sections, we provide an overview of dabigatran etexilate, with a special focus on issues that are pertinent to hospitalists and the hospitalized patient.

PHARMACOLOGY OF DABIGATRAN ETEXILATE
Pharmacokinetics and Pharmacodynamics of Dabigatran Etxetilate
A comparison of the pharmacokinetic (PK) and pharmacodynamic (PD) properties of dabigatran etexilate (dabigatran) and warfarin are presented in Table 1.

Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. In the following sections, we provide an overview of dabigatran etexilate, with a special focus on issues that are pertinent to hospitalists and the hospitalized patient.

Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. In the following sections, we provide an overview of dabigatran etexilate, with a special focus on issues that are pertinent to hospitalists and the hospitalized patient.

Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. In the following sections, we provide an overview of dabigatran etexilate, with a special focus on issues that are pertinent to hospitalists and the hospitalized patient.

Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. Dabigatran etexilate (Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc.) has recently become the first oral anticoagulant to be available for wide clinical use since the 1950s. In the following sections, we provide an overview of dabigatran etexilate, with a special focus on issues that are pertinent to hospitalists and the hospitalized patient.
coagulation by converting fibrinogen to fibrin, amplifying its own generation by feedback activation of factors V, VIII, and XI, and by activating platelets (Fig. 1).16 Dabigatran is a direct thrombin inhibitor that acts independently of antithrombin to inhibit both free and clot-bound thrombin.17,18 The bioavailability of dabigatran after oral intake is low (6%–7%).19–23 After absorption, the prodrug is rapidly converted by plasma and hepatic esterases to the active drug dabigatran, but it is not metabolized by the CYP-450 system, therefore reducing the potential for drug–drug interactions.8,23–28 The long half-life of dabigatran allows for once or twice daily dosing.21,24 The PK profile of dabigatran is predictable, with minimal inter- and intraindividual variation.21,22

Dabigatran is packaged in capsules that are hygroscopic. Therefore, the capsules should be stored in the original container with the cap tightly closed. Exposure of dabigatran capsules to air for prolonged periods outside the original container can result in deterioration of the active compound and reduced efficacy.27,28 Dabigatran capsules contain tartaric acid which is necessary to facilitate dissolution of the medication in the gastrointestinal tract for optimal absorption.2 Breaking the capsules or removing the drug from the capsule can result in increased exposure. Therefore, dabigatran capsules should be taken intact, and patients should be instructed that dabigatran capsules should not be broken, chewed, or opened before administration.28 Alternative anticoagulants should be used if patients cannot swallow the capsule intact for any reason (eg, intubated patients).

**Dabigatran and Drug and Food Interactions**

Dabigatran acts as a substrate of the transporter protein P-glycoprotein (P-gp), which is also involved in the transport of many other drugs.5,16 P-gp is an efflux pump that functions to prevent the absorption of drugs in the intestine or increase the renal excretion of drugs that are P-gp substrates.25 Inhibitors of P-gp increase the serum concentrations of P-gp substrates, whereas P-gp inducers reduce the concentrations of these medications.13 Examples of P-gp inhibitors include clarithromycin, quinidine, and verapamil, whereas rifampin, pantoprazole, and St John’s wort are known to induce P-gp.5,24,26 As an illustration, the coadministration of dabigatran and amiodarone, a known P-gp inhibitor, increases the area under the curve of drug plasma–concentration–time of dabigatran by ≈60% without significantly affecting levels of amiodarone.5,27 Nevertheless, dagibatran’s prescribing information in the United States advises that the “P-gp inhibitors ketoconazole, verapamil, amiodarone, quinidine, and clarithromycin do not require dose adjustments, although these results should not be extrapolated to other P-gp inhibitors.”1,28 In addition, the manufacturer recommends generally avoiding the concomitant use of the potent P-gp inducer rifampin with dabigatran, whereas the European Medicines
Agency advises caution in the coadministration of rifampin or St John’s wort with dabigatran.\(^{27,28}\)

Not all P-gp substrates result in clinically significant interactions with dabigatran (eg, digoxin, diclofenac, and atorvastatin).\(^{19,29}\) The use of nonsteroidal anti-inflammatory drugs and aspirin may increase the risk of bleeding in patients using dabigatran.\(^{5,26,27}\) It is not recommended to coadminister certain anti-platelet agents (such as clopidogrel, prasugrel, or ticlopidine) with dabigatran.\(^{26,30}\) Although the use of proton pump inhibitors such as pantoprazole leads to a \(\approx30\)% decrease in the area under the curve of dabigatran, coadministration of pantoprazole and other proton pump inhibitors with dabigatran in clinical trials did not affect bleeding risk or efficacy.\(^{27}\) Attention to potential drug interactions with dabigatran is important, because dabigatran is not usually monitored. Food interactions with dabigatran appear to be low, and therefore dabigatran can probably be taken with or without food, but caution is advised given the limited postmarketing experience with dabigatran.\(^{30}\) An excellent review of drug and dietary interactions of dabigatran has been published recently.\(^{5}\)

### Use of Dabigatran in Patients With Liver or Renal Impairment

Approximately 80% of dabigatran is excreted, largely unchanged, by the kidneys in healthy subjects.\(^{19}\) Patients with severe renal impairment (creatinine clearance \([\text{CrCL}]\), \(\leq30\) mL/min) were excluded from phase 3 trials that evaluated dabigatran.\(^{31–35}\) A small study in patients with renal impairment showed a linear correlation between renal function and renal clearance of dabigatran, with proportional increases in the anticoagulant effects of dabigatran with decreasing renal function.\(^{36}\) For patients on hemodialysis, 62%–68% of the dose was removed.\(^{36}\) The authors recommended avoidance of dabigatran in severe renal impairment, and a dose reduction was recommended for moderate renal impairment (\([\text{CrCL}]\), 31–50 mL/min).\(^{13,36}\) Despite exclusion of patients with \([\text{CrCL}]\) of \(\leq30\) mL/min from all phase 3 trials of dabigatran and the relative contraindication of the use of dabigatran in this patient population, the US Food and Drug Administration (FDA) approved a reduced dose of 75 mg twice daily for patients with \([\text{CrCL}]\) of 15–30 mL/min, but no dosing recommendations were made for patients with \([\text{CrCL}]\) of \(\leq15\) mL/min or for patients on dialysis.\(^{13,28,36}\) We believe that dabigatran should be used with great caution in patients with \([\text{CrCL}]\) 15–30 mL/min given the limited outcome data in these patients, and alternative anticoagulants should be strongly considered for these patients until more data are available.

Less than 20% of the dabigatran dose is conjugated in the liver and subsequently secreted in the biliary system.\(^{19,23}\) Stangier et al. showed that moderate hepatic impairment does not affect the PK/PD or safety profile of dabigatran and concluded that dabigatran can be given to those patients without dose adjustment.\(^{37}\) On the other hand, severe hepatic impairment (Child-Pugh class B or C cirrhosis) and an alanine aminotransferase level more than 2 to 3 times the upper limit of normal were used as exclusion criteria in most of the phase 3 trials that evaluated dabigatran.\(^{16,24,34,35,38}\) The hepatic toxicity noted with the first generation oral direct thrombin inhibitor, ximelagatran, has not been seen with dabigatran in clinical trials, although long-term postmarketing data are lacking.\(^{32,34,35,38–40}\)

### EFFICACY OF DABIGATRAN

In this section, we provide a brief review of the major phase 3 trials that evaluated dabigatran for different indications (see references 13, 16, and 24 for recent detailed reviews of the clinical trials of dabigatran).

### Dabigatran for Thromboprophylaxis in Patients with Atrial Fibrillation

The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial was a prospective, noninferiority, phase 3 study of dabigatran that was the basis for its FDA approval in patients with nonvalvular AF.\(^{35,44}\) In RE-LY, 18,113 AF patients with another thromboembolic risk factor were randomized to receive fixed doses of dabigatran (110 mg or 150 mg twice daily) or adjusted-dose warfarin.\(^{35}\) The median duration of follow-up was 2 years and the primary outcome was stroke or systemic embolism. The
primary outcome occurred in 1.69% per year in the warfarin group versus 1.53% per year in the group receiving 110 mg of dabigatran twice daily (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74–1.11; P < 0.001 for noninferiority) and 1.11% per year in the group receiving 150 mg of dabigatran twice daily (relative risk, 0.86; 95% CI, 0.53–0.82; P < 0.001 for superiority). The rate of major bleeding was 3.36% per year in the warfarin group versus 2.71% per year in the dabigatran 110 mg group (P = 0.003) and 3.11% per year in the dabigatran 150 mg group (P = 0.31). Intracranial bleeds were significantly less common in both dabigatran groups than with warfarin. Major gastrointestinal bleeding rate was significantly higher in the dabigatran groups than with warfarin. Major gastrointestinal bleeds were significantly less common in both dabigatran with and without prior VKA treatment.45,46

**Dabigatran for Prevention of Venous Thromboembolism After Major Orthopedic Procedures**

Without thromboprophylaxis, the incidence of venous thromboembolism (VTE) following major orthopedic surgery is 40%–60%.37 Nevertheless, many patients do not receive appropriate thromboprophylaxis after orthopedic surgery, in part due to the limitations of VKAs and the inconvenience of low molecular weight heparin (LMWH) injections.48

**RE-NOVATE Trial**

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II trial) was a randomized, double-blind, noninferiority phase 3 trial that compared dabigatran versus SC enoxaparin for extended thromboprophylaxis in patients undergoing THR.38 A total of 2055 patients were randomized to 28–35 days of oral dabigatran, 220 mg once daily, starting with a half-dose 1–4 hours after surgery, or SC enoxaparin 40 mg once daily, starting the evening before surgery. The primary efficacy outcome was the same as that in the RE-NOVATE trial. The primary efficacy outcome occurred in 7.7% of the dabigatran group versus 8.8% of the enoxaparin group (risk difference, −1.1%; 95% CI, −3.8 to 1.6%; P < 0.0001 for the prespecified noninferiority margin. Major VTE plus VTE-related death occurred in 2.2% of the dabigatran group versus 4.2% of the enoxaparin group (risk difference, −1.9%; 95% CI, −3.6% to −0.2%; P = 0.03). Major bleeding occurred in 1.4% of the dabigatran group and 0.9% of the enoxaparin group (P = 0.40). It was concluded that extended prophylaxis with oral dabigatran 220 mg once daily was not inferior to SC enoxaparin 40 mg once daily for prevention of VTE after THR. The safety profiles were similar between the 2 arms.38

**RE-MODEL Trial**

In the Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement (RE-MODEL trial) phase 3 trial, 2076 patients who underwent total knee replacement (TKR) were randomized to receive dabigatran 150 mg or 220 mg once daily starting with a half-dose 1–4 hours after surgery, or SC enoxaparin 40 mg once daily starting the evening before surgery, for 6–10 days.32 Patients were followed-up for 3 months. The primary efficacy outcome was a composite of total VTE (venographic or symptomatic) and mortality during treatment. The primary efficacy outcome occurred in 37.7% of the enoxaparin group versus 36.4% of the dabigatran 220 mg group (AD, −1.3%; 95% CI, −7.3 to 4.6) and 40.5% of the 150 mg group (AD, 2.8%; 95% CI, −3.1 to 8.7). The incidence of major bleeding did not differ between the groups (1.3% versus 1.5% and 1.3%, respectively). The conclusion was that dabigatran (220 mg or 150 mg) was not inferior to enoxaparin for prevention of
Dabigatran for Treatment of Acute VTE

RE-COVER was a large, randomized, noninferiority phase 3 trial that randomized 2564 patients with acute symptomatic proximal lower extremity deep vein thrombosis or pulmonary embolism to 6 months of dabigatran 150 mg twice daily or dose-adjusted warfarin (INR 2/3). All patients initially received parenteral anticoagulation (LMWH or unfractionated heparin [UFH]) for a median of 9 days. Patients in the warfarin group spent 60% of the time in the therapeutic range. In the dabigatran arm, 2.4% had recurrent VTE versus 2.1% in the warfarin arm (P < 0.001 for the prespecified noninferiority margin). Major bleeding occurred in 1.6% of patients in the dabigatran arm and 1.9% in the warfarin arm (hazard ratio, 0.82; 95% CI, 0.45–1.48). There was no difference in the other safety endpoints (acute coronary syndrome, abnormal liver function tests and deaths). Adverse events (especially gastrointestinal) leading to discontinuation of the study drug occurred in 9% of patients assigned to dabigatran and 6.8% of patients assigned to warfarin (P = 0.05). It was concluded that a fixed dose of dabigatran was not inferior to warfarin for treatment of VTE, with a similar safety profile. It is important to note that the first dose of dabigatran was given after a median of 9 days of parenteral anticoagulation therapy, so the findings of this study do not provide data regarding the use of dabigatran as initial monotherapy for acute VTE. 

The results of additional randomized trials evaluating the use of dabigatran for acute VTE treatment (RE-COVER II and secondary prevention of VTE (RE-MEDY and RE-SONATE) are expected soon.

SAFETY OF DABIGATRAN

Aside from the bleeding risks discussed earlier, the most commonly reported side effect of dabigatran was dyspepsia. Dyspepsia occurred twice as frequently in patients taking dabigatran versus warfarin in the RE-LY trial (11.5% vs 5.8%). One possible explanation for the higher incidence of dyspepsia is the tartaric acid component in dabigatran capsules. In the RE-LY study, myocardial infarction occurred more commonly in the dabigatran arms (0.72% with 110 mg and 0.74% with 150 mg) than the warfarin arm (0.53%, P = 0.07 and 0.048, respectively). It has been postulated that this observation could be related to a greater efficacy of warfarin for the prevention of myocardial infarction rather than an adverse effect of dabigatran. There was no increase in acute coronary syndrome rates noted with dabigatran in the other phase 3 trials. No increased risk of elevated liver function test has been noted with dabigatran, but long-term data are unavailable.

MANAGEMENT OF SPECIAL SITUATIONS THAT MAY ARISE IN THE USE OF DABIGATRAN

Switching From Warfarin to Dabigatran and Vice Versa

When converting patients from warfarin to dabigatran, it is recommended that dabigatran be started once the INR falls below the lower limit of the desired therapeutic range. Conversely, when switching from dabigatran to warfarin, the manufacturer recommends starting warfarin based on renal function (Table 2). It should be noted that because dabigatran can increase the INR, the INR will better reflect warfarin’s effect after dabigatran has been stopped for at least 2 days.

Bridging from Dabigatran to Parenteral Anticoagulants and Vice Versa

For patients currently receiving a parenteral anticoagulant, the manufacturer recommends starting dabigatran 0–2 hours before the next administration time for parenteral anticoagulants (eg, LMWH) or at the time of discontinuation for continuously infused parenteral drugs (eg, intravenous UFH). For patients currently taking dabigatran who are transitioning to a parenteral anticoagulant, it is recommended to wait 12 hours (CrCl ≥30 mL/min) or 24 hours (CrCl <30 mL/min) after the last dose of dabigatran before initiating treatment with a parenteral anticoagulant.
Management of Dabigatran Before Elective and Urgent Invasive Procedures

Patients who undergo invasive procedures in the presence of therapeutic levels of dabigatran are at an increased risk of bleeding. The manufacturer recommends holding dabigatran for at least 24 hours before elective surgery depending on the degree of renal impairment and the risk of bleeding. Table 3 lists recommendations on the timing of discontinuation of dabigatran before a procedure. If emergent/urgent surgery is necessary for a patient who is on dabigatran, the risk of bleeding should be weighed against the urgency of the intervention. As mentioned earlier, the ECT or the Hemoclot Thrombin Inhibitor assay are the preferred tests for measurement of dabigatran effects, but they are not standardized or widely clinically available. Instead, prolongation of the TT (preferably) or the aPTT can be used to determine the presence of dabigatran.

Overdose and Toxicity With Dabigatran

Accidental or intentional overdose, or accumulation of dabigatran due to renal impairment, may lead to hemorrhagic complications. Unlike warfarin and heparin, there is no antidote for dabigatran. There are no widely available, reliable laboratory tests to measure the anticoagulant activity of dabigatran, and evidence-based guidelines to manage dabigatran toxicity do not exist. Therefore, in the event of dabigatran toxicity, treatment is largely supportive. Management of toxicity is dependent on whether the overdose/accumulation is accompanied by bleeding or not. For overdose, interventions include adequate diuresis and the use of activated charcoal to reduce the absorption of dabigatran (within 2 hours of ingestion). In the event of bleeding, proposed measures include application of mechanical pressure to the sites of bleeding and infusion of pro-coagulant blood products such as activated prothrombin complex concentrates (eg, FEIBA VH, Baxter) or recombinant human activated factor VIIa (NovoSeven, NovoNordisk) (reviewed in references 26 and 42). In life-threatening situations, hemodialysis could be considered, because it can remove ≈60% of the drug within 2–3 hours. Hemoperfusion over a charcoal filter or large volume hemofiltration have also been suggested in extreme situations. Acknowledging their limitations, the ECT, TT, or aPTT may be used to direct therapy.

Pregnancy and Dabigatran Therapy

Dabigatran is a class C drug during pregnancy, and there are no studies of dabigatran in pregnant women. Animal studies with dabigatran showed decreased fertility of pregnant rats; therefore, the risks and benefits of dabigatran therapy during pregnancy should be weighed carefully.

CONCLUSIONS

Dabigatran is a novel, oral direct thrombin inhibitor that exhibits several advantages over warfarin. The predictable pharmacokinetic profile and minimal food and drug interactions of dabigatran allow for a fixed-dosing regimen and obviate the need for routine laboratory monitoring. However, this apparent advantage is also a disadvantage. The lack of a reliable method to monitor dabigatran makes it more difficult to assess compliance, measure the impact of drug interactions, evaluate for toxicity, and determine bona fide therapeutic failure versus noncompliance in the event of breakthrough thromboembolism. Other limitations of dabigatran include the lack of an antidote and the dependence on normal renal function for elimination, with the potential for drug accumulation and toxicity with renal impairment. The noninferiority design of the clinical trials that evaluated dabigatran, the absence of long-term safety and efficacy data, and issues related to the cost effectiveness of dabigatran should be considered when prescribing this agent. More studies are needed to assess dabigatran in special patient populations (eg, the elderly, patients with renal and hepatic impairment, pediatric and pregnant patients) and to better understand dabigatran–drug interactions.

As more novel oral anticoagulant agents, such as factor Xa inhibitors, become available for clinical use, comparative studies will need to be performed to better define the role of each agent for specific
indications. In the future, it might be possible to tailor the choice of the oral anticoagulant to the individual patient not only on the basis of the clinical indication but also the specific patient characteristics and possible drug interactions. For example, rivaroxaban (Xarelto®) is an oral direct factor Xa that was recently approved in the United States for VTE thromboprophylaxis following orthopedic surgery and in patients with non-valvular atrial fibrillation. Similar to dabigatran, rivaroxaban exhibits predictable PK and PD that allow fixed once or twice daily dosing and obviate the need for routine monitoring of its anticoagulant effects. Unlike dabigatran, rivaroxaban is an active drug and not a prodrug, and has a significantly higher bioavailability than dabigatran (>80% vs 6%). In addition, the levels of rivaroxaban can be affected by drugs that interfere with both P-gp and the hepatic CYP-450 system, compared with dabigatran, which is affected only by drugs that affect P-gp.

Disclosures: Michael B. Streiff is a consultant for sanofi-aventis, Daiichi-Sankyo, Eisai, and Janssen Pharmaceutical, Inc.; has received research grants from Bristol-Myers Squibb and sanofi-aventis; has received lecture honoraria from sanofi-aventis and Ortho-McNeil; and has received payment to develop presentations from Ortho-McNeil.

References
12. Stangier J, Rathgen K, Stahle H, Ruiz J. Rivaroxaban, an active drug and not a prodrug, and has a significantly higher bioavailability than dabigatran (>80% vs 6%). In addition, the levels of rivaroxaban can be affected by drugs that interfere with both P-gp and the hepatic CYP-450 system, compared with dabigatran, which is affected only by drugs that affect P-gp.


